课题基金 / 基金详情

PHASE I/II TRIAL OF PIXY 321 FOR OVARIAN CANCER

PHASE I/II TRIAL OF PIXY 321 FOR OVARIAN CANCER
PIXY 321 治疗卵巢癌的 I/II 期试验
批准号：
3785793
负责人：
JAMES SPEYER
金额：
$0.0万
依托单位：
NEW YORK UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3785793
关键词：
chimeric proteins cis platinum compound clinical trials colony stimulating factor combination chemotherapy cyclophosphamide drug screening /evaluation female human subject human therapy evaluation interleukin 3 neoplasm /cancer immunotherapy ovary neoplasms

项目摘要

项目成果

JAMES SPEYER的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a phase I/II study to evaluate the safety of daily subcutaneous injections of PIXY321, which is a fusion protein combining granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-3 (IL-3), to patients with ovarian carcinoma following chemotherapy with cyclophosphamide and carboplatin.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protocol Review and Monitoring
WEEKLY ONE HOUR PACLITAXEL IN REFRACTORY METASTATIC BREAST CANCER
WEEKLY ONE HOUR PACLITAXEL IN REFRACTORY METASTATIC BREAST CANCER
DEXRAZOXANE, DOXORUBICIN & ESCALATING DOSES OF PACLITAXEL IN ADVANCED BREAST CA